Close Menu

More articles about Business, Policy & Funding

The companies initially plan to expand the commercialization of Sophia's DDM analytics platform and Hitachi's digital healthcare technology in certain geographic areas.

The California-based firms also plan to collaborate on advancing genomics and artificial intelligence-guided oncology tools. 

Although the logistics still need to be worked out, the partners hope to streamline oncologists' experience ordering tests that can inform patient care.

The first project is a proposal to advance a digital ID badge for tracking cell therapies from manufacturing, through shipment, to patient delivery.

NeoGenomics will offer Trapelo's clinical decision support system to providers, payors, and labs to aid precision oncology across all healthcare settings.

CellMax also completed a Series C financing round to speed up development of itsFirstSight liquid biopsy test to detect colorectal cancer and precancer polyps.

Japanese regulators approved the drug based on results of the FIGHT-202 trial showing that 36 percent of patients on pemigatinib responded to the treatment.

In the Impower010 study, the PD-L1 inhibitor had promising activity in early-stage NSCLC patients, especially in those with PD-L1-positive tumors.

News items for the week of March 15, 2021. 

While more data are collected, the CDF can provide the regimen to advanced, HRD-positive ovarian cancer patients after first-line platinum chemo and bevacizumab.

The company plans to transition its DetermaIO test from research to clinical use and to launch a new research product for immunotherapy monitoring by the end of this year.

The firms plan to build a workflow for CTC isolation directly from a patient's bloodstream for single-cell downstream molecular analysis such as sequencing, genotyping, or digital PCR.

The drug will be available for untreated chronic lymphocytic leukemia patients with a 17p deletion or TP53 mutation.

Bioinformatics firm M2Gen will provide Merck with deidentified clinical and genomics data to aid in oncology drug discovery and development.

The company's test will identify patients who have dysregulated HER2 and c-MET signaling despite having normal HER2 expression in tumors.

The company will use the funds to advance its lead cell therapy candidate for the treatment of HER2-positive solid tumors and other products.

BioMark Diagnostics has been collaborating on the test with the Metabolomics Innovation Centre at the University of Alberta since early 2015.

The company will explore the activity of its lead candidate, BCA101, in several molecularly defined cohorts in the dose-expansion portion of an ongoing Phase I/II trial.

The funding will advance Monte Rosa's lead candidate targeting the GSPT1 protein in solid tumors.

Pages